Orthofix Medical, a specialized global medical device company, has faced persistent operating losses over recent years despite strategic efforts including the merger with SeaSpine. Its portfolio spans implantable spinal devices, bone growth stimulation technologies, and limb reconstruction systems. The company’s future growth depends on leveraging clinical evidence and innovation, physician collaboration, new product launches, and operational synergies from its merger. While cash flow trends are improving, capital expenditures remain high, impacting free cash flow. Risks include integration headwinds, competitive pressures, regulatory hurdles, and healthcare consolidation influencing pricing dynamics.